RESUMO
BACKGROUND: Mechanomyography is the traditional gold standard research technique for quantitative assessment of neuromuscular blockade. Mechanomyography directly measures the isometric force generated by the thumb in response to ulnar nerve stimulation. Researchers must construct their own mechanomyographs since commercial instruments are no longer available. A mechanomyograph was constructed, and its performance was compared against an archival mechanomyography system from the 1970s that utilized an FT-10 Grass force transducer, hypothesizing that train-of-four ratios recorded on each device would be equivalent. METHODS: A mechanomyograph was constructed using 3D-printed components and modern electronics. An archival mechanomyography system was assembled from original components, including an FT-10 Grass force transducer. Signal digitization for computerized data collection was utilized instead of the original paper strip chart recorder. Both devices were calibrated with standard weights to demonstrate linear voltage response curves. The mechanomyographs were affixed to opposite arms of patients undergoing surgery, and the train-of-four ratio was measured during the onset and recovery from rocuronium neuromuscular blockade. RESULTS: Calibration measurements exhibited a positive linear association between voltage output and calibration weights with a linear correlation coefficient of 1.00 for both mechanomyography devices. The new mechanomyograph had better precision and measurement sensitivity than the archival system: 5.3 mV versus 15.5 mV and 1.6 mV versus 5.7 mV, respectively (P < 0.001 for both). A total of 767 pairs of train-of-four ratio measurements obtained from eight patients had positive linear association (R 2 = 0.94; P < 0.001). Bland-Altman analysis resulted in bias of 3.8% and limits of agreement of -13% and 21%. CONCLUSIONS: The new mechanomyograph resulted in similar train-of-four ratio measurements compared to an archival mechanomyography system utilizing an FT-10 Grass force transducer. These results demonstrated continuity of gold standard measurement of neuromuscular blockade spanning nearly 50 yr, despite significant changes in the instrumentation technology.
Assuntos
Bloqueio Neuromuscular , Rocurônio , Nervo Ulnar , Humanos , Miografia/métodos , Transdutores , Bloqueio Neuromuscular/métodos , Bloqueadores Neuromusculares/administração & dosagem , Bloqueadores Neuromusculares/uso terapêutico , Fármacos Neuromusculares não Despolarizantes , Rocurônio/administração & dosagem , Rocurônio/uso terapêutico , Nervo Ulnar/patologia , Nervo Ulnar/cirurgiaRESUMO
Respiratory and airway-protective muscle weakness caused by the blockade of neuromuscular transmission is a major cause of early mortality from snakebite envenoming (SBE). Once weakness is manifest, antivenom appears to be of limited effectiveness in improving neuromuscular function. Herein, we review the topic of venom-induced neuromuscular blockade and consider the utility of adopting clinical management methods originally developed for the safe use of neuromuscular blocking agents by anesthesiologists in operating rooms and critical care units. Failure to quantify neuromuscular weakness in SBE is predicted to cause the same significant morbidity that is associated with failure to do so in the context of using a clinical neuromuscular block in surgery and critical care. The quantitative monitoring of a neuromuscular block, and an understanding of its neurophysiological characteristics, enables an objective measurement of weakness that may otherwise be overlooked by traditional clinical examination at the bedside. This is important for the initial assessment and the monitoring of recovery from neurotoxic envenoming. Adopting these methods will also be critical to the conduct of future clinical trials of toxin-inhibiting drugs and antivenoms being tested for the reversal of venom-induced neuromuscular block.
Assuntos
Bloqueio Neuromuscular , Bloqueadores Neuromusculares , Mordeduras de Serpentes , Humanos , Mordeduras de Serpentes/terapia , Mordeduras de Serpentes/tratamento farmacológico , Paralisia/tratamento farmacológico , Bloqueio Neuromuscular/métodos , Bloqueadores Neuromusculares/uso terapêutico , Antivenenos/uso terapêuticoRESUMO
BACKGROUND: The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis. METHODS: We analyzed a convenience sample of patients with COVID-19 and moderate-to-severe ARDS, admitted to 244 intensive care units within the COVID-19 Critical Care Consortium, from February 1, 2020, through October 31, 2021. Patients undergoing at least 2 days and up to 3 consecutive days of NMBAs (NMBA treatment), within 48 h from commencement of IMV were compared with subjects who did not receive NMBAs or only upon commencement of IMV (control). The primary objective in the PS-matched cohort was comparison between groups in 90-day in-hospital mortality, assessed through Cox proportional hazard modeling. Secondary objectives were comparisons in the numbers of ventilator-free days (VFD) between day 1 and day 28 and between day 1 and 90 through competing risk regression. RESULTS: Data from 1953 patients were included. After propensity score matching, 210 cases from each group were well matched. In the PS-matched cohort, mean (± SD) age was 60.3 ± 13.2 years and 296 (70.5%) were male and the most common comorbidities were hypertension (56.9%), obesity (41.1%), and diabetes (30.0%). The unadjusted hazard ratio (HR) for death at 90 days in the NMBA treatment vs control group was 1.12 (95% CI 0.79, 1.59, p = 0.534). After adjustment for smoking habit and critical therapeutic covariates, the HR was 1.07 (95% CI 0.72, 1.61, p = 0.729). At 28 days, VFD were 16 (IQR 0-25) and 25 (IQR 7-26) in the NMBA treatment and control groups, respectively (sub-hazard ratio 0.82, 95% CI 0.67, 1.00, p = 0.055). At 90 days, VFD were 77 (IQR 0-87) and 87 (IQR 0-88) (sub-hazard ratio 0.86 (95% CI 0.69, 1.07; p = 0.177). CONCLUSIONS: In patients with COVID-19 and moderate-to-severe ARDS, short course of NMBA treatment, applied early, did not significantly improve 90-day mortality and VFD. In the absence of definitive data from clinical trials, NMBAs should be indicated cautiously in this setting.
Assuntos
Tratamento Farmacológico da COVID-19 , Bloqueadores Neuromusculares , Síndrome do Desconforto Respiratório , Idoso , Feminino , Humanos , Unidades de Terapia Intensiva , Masculino , Pessoa de Meia-Idade , Bloqueadores Neuromusculares/uso terapêutico , Pontuação de Propensão , Respiração Artificial , Síndrome do Desconforto Respiratório/tratamento farmacológicoAssuntos
Atracúrio/análogos & derivados , Atracúrio/efeitos adversos , COVID-19/complicações , Bloqueadores Neuromusculares/efeitos adversos , SARS-CoV-2/isolamento & purificação , Atracúrio/uso terapêutico , Dispneia , Humanos , Masculino , Hipertermia Maligna , Pessoa de Meia-Idade , Bloqueadores Neuromusculares/uso terapêuticoRESUMO
BACKGROUND: Depressor anguli oris muscle hypertonicity in synkinetic facial paralysis patients may have an overpowering antagonistic effect on facial symmetry. Depressor anguli oris muscle block is a crucial diagnostic test before any treatment planning. Presented is the largest patient cohort analysis to date on static and dynamic facial symmetry changes after depressor anguli oris muscle block. METHODS: Unilateral synkinetic patients with depressor anguli oris muscle hypertonicity were included. Resting symmetry and smile modiolus angle, excursion, and exposure of teeth were measured on both synkinetic and healthy hemifaces before and after depressor anguli oris muscle block using Emotrics and FaceGram photographic analyses. RESULTS: Thirty-six patients were included. Before depressor anguli oris block, resting modiolus height was elevated on the synkinetic side (p = 0.047). During open-mouth smile, reduced modiolus angle (p < 0.0001), modiolus excursion (p < 0.0001), and exposure of teeth (p < 0.0001) were observed on the synkinetic hemiface. After depressor anguli oris block, resting modiolus height became symmetric (p = 0.64). During open-mouth smile, modiolus angle and exposure of teeth significantly increased (both p < 0.0001); excursion did not improve on the synkinetic side (p = 0.13) but unexpectedly improved in open-mouth smile on the healthy side (p = 0.0068). CONCLUSIONS: Depressor anguli oris muscle block improved resting symmetry and modiolus angle and exposure of teeth during smile, demonstrating the inhibitory mimetic role of a hypertonic depressor anguli oris muscle in synkinesis. It is a critical diagnostic and communication tool in the assessment and treatment planning of depressor anguli oris muscle hypertonicity, suggesting the potential effects of future depressor anguli oris myectomy. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
Assuntos
Assimetria Facial/tratamento farmacológico , Músculos Faciais/fisiopatologia , Paralisia Facial/fisiopatologia , Hipertonia Muscular/tratamento farmacológico , Bloqueio Neuromuscular/métodos , Sincinesia/etiologia , Adolescente , Adulto , Idoso , Estudos de Casos e Controles , Assimetria Facial/etiologia , Expressão Facial , Músculos Faciais/efeitos dos fármacos , Paralisia Facial/diagnóstico , Paralisia Facial/cirurgia , Feminino , Humanos , Injeções Intramusculares , Lidocaína/farmacologia , Lidocaína/uso terapêutico , Masculino , Pessoa de Meia-Idade , Hipertonia Muscular/etiologia , Bloqueadores Neuromusculares/farmacologia , Bloqueadores Neuromusculares/uso terapêutico , Cuidados Pré-Operatórios/métodos , Estudos Retrospectivos , Sorriso , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND: Patients undergoing thoracoscopic procedures may be at high-risk for incomplete neuromuscular recovery and associated complications. The aim of this clinical investigation was to assess the incidence of postoperative residual neuromuscular blockade in adult thoracic surgical patients administered neostigmine or sugammadex when optimal dosing and reversal strategies for these agents were used. The effect of choice of reversal agent on hypoxemic events and signs and symptoms of muscle weakness were also determined. Additionally, operative conditions in each group were graded by surgeons performing the procedures. METHODS: Two hundred patients undergoing thoracoscopic surgical procedures were enrolled in this nonrandomized controlled trial. One hundred consecutive patients maintained at moderate levels of neuromuscular blockade were reversed with neostigmine (neostigmine group) followed by 100 consecutive patients given sugammadex to antagonize deeper levels of neuromuscular blockade (sugammadex group). Anesthetic and neuromuscular management were standardized. Surgeons rated operative conditions at the conclusion of the procedure on a 4-point scale (grade 1 = excellent to grade 4 = poor). Train-of-four ratios were measured immediately before extubation and at PACU admission (primary outcomes). Postoperatively, patients were assessed for adverse respiratory events and 11 signs and 16 symptoms of muscle weakness. RESULTS: The 2 groups were similar in intraoperative management characteristics. The percentage of patients with residual neuromuscular blockade, defined as a normalized train-of-four ratio <0.9, was significantly greater in the neostigmine group than the sugammadex group at both tracheal extubation (80% vs 6%, respectively, P < .0001) and PACU admission (61% vs 1%, respectively, P < .0001). Patients in the neostigmine group had less optimal operative conditions (median score 2 [good] versus 1 [excellent] in the sugammadex group; P < .0001), and more symptoms of muscle weakness were present in these subjects (median number [interquartile range] 4 [1-8] vs 1 [0-2] in the sugammadex group, P < .0001). No differences between groups in adverse airway events were observed. CONCLUSIONS: Despite the application of strategies documented to reduce the risk of residual neuromuscular blockade, a high percentage of thoracoscopic patients whose neuromuscular blockade was reversed with neostigmine were admitted to the PACU with clinical evidence of residual paralysis. In contrast, muscle weakness was rarely observed in patients whose neuromuscular blockade was antagonized with sugammadex.
Assuntos
Recuperação Demorada da Anestesia , Neostigmina/uso terapêutico , Bloqueio Neuromuscular , Bloqueadores Neuromusculares/uso terapêutico , Junção Neuromuscular/efeitos dos fármacos , Sugammadex/uso terapêutico , Toracoscopia , Idoso , Idoso de 80 Anos ou mais , Período de Recuperação da Anestesia , Feminino , Humanos , Illinois , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/induzido quimicamente , Debilidade Muscular/fisiopatologia , Neostigmina/efeitos adversos , Bloqueio Neuromuscular/efeitos adversos , Bloqueadores Neuromusculares/efeitos adversos , Junção Neuromuscular/fisiopatologia , Monitoração Neuromuscular , Recuperação de Função Fisiológica , Sugammadex/efeitos adversos , Toracoscopia/efeitos adversos , Fatores de Tempo , Resultado do TratamentoRESUMO
BACKGROUND: Bladder pain syndrome (BPS), which includes the condition of interstitial cystitis, is a poorly understood clinical condition for which patients present with varying symptoms. Management of BPS is challenging for both patients and practitioners. At present, there is no universally accepted diagnosis and diverse causes have been proposed. This is reflected in wide-ranging treatment options, used alone or in combination, with limited evidence. A network meta-analysis (NMA) simultaneously comparing multiple treatments may help to determine the best treatment options for patients with BPS. OBJECTIVES: To conduct a network meta-analysis to assess the effects of interventions for treating people with symptoms of bladder pain syndrome (BPS). SEARCH METHODS: We searched the Cochrane Incontinence Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL, in the Cochrane Library), MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and handsearched journals and conference proceedings (searched 11 May 2018) and the reference lists of relevant articles. We conducted a further search on 5 June 2019, which yielded four small studies that were screened for eligibility but were not incorporated into the review. SELECTION CRITERIA: We included randomised controlled trials (RCTs) and quasi-RCTs of interventions for treating adults with BPS. All types of interventions (including conservative, pharmacological and surgical) were eligible. DATA COLLECTION AND ANALYSIS: We assessed the risk of bias of included studies using Cochrane's 'Risk of bias' tool. Primary outcomes were the number of people cured or improved, pain, frequency and nocturia. For each outcome, random-effects NMA models were fitted using WinBUGS 1.4. We monitored median odds ratios (ORs) for binary outcomes and mean differences (MDs) for continuous outcomes with 95% credible intervals (Crls). We compared results of the NMA with direct evidence from pairwise meta-analysis of head-to-head trials. We used the CINeMA tool to assess the certainty of evidence for selected treatment categories. MAIN RESULTS: We included 81 RCTs involving 4674 people with a median of 38 participants (range 10 to 369) per RCT. Most trials compared treatment against control; few trials compared two active treatments. There were 65 different active treatments, and some comparisons were informed by direct evidence from only one trial. To simplify, treatments were grouped into 31 treatment categories by mode of action. Most studies were judged to have unclear or high risk of bias for most domains, particularly for selection and detection bias. Overall, the NMA suggested that six (proportion cured/improved), one (pain), one (frequency) and zero (nocturia) treatment categories were effective compared with control, but there was great uncertainty around estimates of effect. Due to the large number of intervention comparisons in this review, we focus on three interventions: antidepressants, pentosan polysulfate (PPS) and neuromuscular blockade. We selected these interventions on the basis that they are given 'strong recommendations' in the EAU Guidelines for management of BPS (EAU Guidelines 2019). We found very low-certainty evidence suggesting that antidepressants were associated with greater likelihood of cure or improvement compared with control (OR 5.91, 95% CrI 1.12 to 37.56), but it was uncertain whether they reduced pain (MD -1.27, 95% CrI -3.25 to 0.71; low-certainty evidence), daytime frequency (MD -2.41, 95% CrI -6.85 to 2.05; very low-certainty evidence) or nocturia (MD 0.01, 95% CrI -2.53 to 2.50; very low-certainty evidence). There was no evidence that PPS had improved cure/improvement rates (OR 0.14, 95% CrI 0.40 to 3.35; very low-certainty evidence) or reduced pain (MD 0.42, 95% CrI -1.04 to 1.91; low-certainty evidence), frequency (MD -0.37, 95% CrI -5.00 to 3.44; very low-certainty evidence) or nocturia (MD -1.20, 95% CrI -3.62 to 1.28; very low-certainty evidence). There was evidence that neuromuscular blockade resulted in greater cure or improvement (OR 5.80, 95% CrI 2.08 to 18.30) but no evidence that it improved pain (MD -0.33, 95% CrI -1.71 to 1.03), frequency (MD -0.91, 95% CrI -3.24, 1.29) or nocturia (MD -0.04, 95% CrI -1.35 to 1.27). The certainty of this evidence was always very low. AUTHORS' CONCLUSIONS: We are uncertain whether some treatments may be effective in treating patients with BPS because the certainty of evidence was generally low or very low. Data were available for a relatively large number of trials, but most had small sample sizes and effects of treatments often could not be estimated with precision. An NMA was successfully conducted, but limited numbers of small trials for each treatment category hampered our ability to fully exploit the advantages of this analysis. Larger, more focused trials are needed to improve the current evidence base.
Assuntos
Cistite Intersticial/terapia , Metanálise em Rede , Antidepressivos/uso terapêutico , Viés , Feminino , Humanos , Masculino , Bloqueadores Neuromusculares/uso terapêutico , Noctúria/terapia , Poliéster Sulfúrico de Pentosana/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
Despite the intense focus on the opioid epidemic and its known association with surgical procedures, there is a paucity of evidence-based literature on pain management in implant-based breast reconstruction (IBR). Herein, we present an updated review of the literature aimed at identifying pain treatment protocols to minimize narcotic use and its associated potential addiction in IBR. A comprehensive review of the published English literature was conducted using Ovid Medline/PubMed Database without timeframe limitations. The inclusion criteria of selected articles presented in this review included studies reporting objective outcomes of pain modulation (preoperatively, intraoperatively and postoperatively) in IBR. Articles for inclusion were stratified based on intervention. A total of 219 articles were identified in the initial search query, with 23 studies meeting the inclusion criteria. Pain optimization interventions in IBR are herein summarized and analyzed based on the reported outcomes of each respective study. There is a substantial need for evidence-based guidelines in the plastic surgery literature for pain optimization without the use of opioids. While this review of studies to date investigates potential solutions, we hope this area of study continues to be a top priority for plastic surgeons to allow for optimized post-operative care for patients following IBR.
Assuntos
Analgésicos/uso terapêutico , Implantes de Mama , Mamoplastia/efeitos adversos , Manejo da Dor/métodos , Dor Pós-Operatória/tratamento farmacológico , Algoritmos , Implante Mamário/efeitos adversos , Deambulação Precoce , Feminino , Humanos , Bloqueio Nervoso , Bloqueadores Neuromusculares/uso terapêutico , Dor Pós-Operatória/prevenção & controle , Dor Pós-Operatória/terapiaRESUMO
PURPOSE OF REVIEW: The present review provides a summary of the literature on recent development of new neuromuscular blocking agents and presents clinically well established and new reversal agents. RECENT FINDINGS: Anesthesiologists are still waiting for the ideal neuromuscular blocking agent with a succinylcholine-like rapid onset and offset without side effects. Recent drug development led to a new series of neuromuscular compounds, called the chlorofumarates such as gantacurium, CW002, and CW011. These drugs have a promising pharmacodynamic profile; importantly, they can rapidly be reversed by L-cysteine adduction without relevant side effects. In addition, a new spectrum of reversal agents are currently examined in preclinical studies: adamgammadex sodium, a modified γ-cyclodextrin derivate that forms an inactive tight inclusion complex with rocuronium or vecuronium and calabadions, capable of reversing both benzylisoquinolines and steroidal neuromuscular blocking agents. SUMMARY: Although the recent advancements in neuromuscular research are very promising, to date, the presented drugs are currently not available for clinical use. Clinical studies will determine the role of these developments in anesthesia practice. Therefore, well established combinations such as rocuronium-sugammadex are popular in clinical practice to offer quick paralysis for intubation and to optimize surgical conditions, while providing a fast neuromuscular recovery at the end of surgery.
Assuntos
Bloqueio Neuromuscular , Bloqueadores Neuromusculares/uso terapêutico , Fármacos Neuromusculares não Despolarizantes/uso terapêutico , Avaliação Pré-Clínica de Medicamentos , Humanos , Isoquinolinas , Maleatos , Rocurônio , SugammadexRESUMO
O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 13 artigos e 8 protocolos.
Assuntos
Humanos , Pneumonia Viral/tratamento farmacológico , Infecções por Coronavirus/tratamento farmacológico , Betacoronavirus/efeitos dos fármacos , Antivirais/uso terapêutico , Avaliação da Tecnologia Biomédica , Imunoglobulinas/uso terapêutico , Estudos Transversais , Estudos de Coortes , Interleucinas/antagonistas & inibidores , Corticosteroides/uso terapêutico , Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico , Leflunomida/uso terapêutico , Hidroxicloroquina/uso terapêutico , Imunossupressores/uso terapêutico , Antibacterianos/uso terapêutico , Antifúngicos/uso terapêutico , Bloqueadores Neuromusculares/uso terapêuticoAssuntos
Betacoronavirus , Infecções por Coronavirus/complicações , Estado Terminal , Sedação Profunda/métodos , Hipnóticos e Sedativos/uso terapêutico , Pneumonia Viral/complicações , Respiração Artificial/efeitos adversos , Síndrome do Desconforto Respiratório/terapia , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/efeitos adversos , Analgésicos Opioides/uso terapêutico , COVID-19 , Sedação Profunda/efeitos adversos , Delírio/induzido quimicamente , Quimioterapia Combinada , Hemodinâmica/efeitos dos fármacos , Humanos , Hipnóticos e Sedativos/administração & dosagem , Hipnóticos e Sedativos/efeitos adversos , Hipnóticos e Sedativos/provisão & distribuição , Complacência Pulmonar/efeitos dos fármacos , Bloqueadores Neuromusculares/administração & dosagem , Bloqueadores Neuromusculares/efeitos adversos , Bloqueadores Neuromusculares/uso terapêutico , Dor Processual/tratamento farmacológico , Dor Processual/etiologia , Dor Processual/prevenção & controle , Pandemias , Propofol/administração & dosagem , Propofol/efeitos adversos , Propofol/uso terapêutico , SARS-CoV-2 , Procedimentos Desnecessários , Desmame do Respirador , Lesão Pulmonar Induzida por Ventilação Mecânica/prevenção & controleRESUMO
Immune response against neuronal and glial cell surface and cytosolic antigens is an important cause of encephalitis. It may be triggered by activation of the immune system in response to an infection (para-infectious), cancer (paraneoplastic), or due to a patient's tendency toward autoimmunity. Antibodies directed toward neuronal cell surface antigens are directly pathogenic, whereas antibodies with intracellular targets may become pathogenic if the antigen is transiently exposed to the cell surface or via activation of cytotoxic T cells. Immune-mediated encephalitis is well recognized and may require intensive care due to status epilepticus, need for invasive ventilation, or dysautonomia. Patients with immune-mediated encephalitis may become critically ill and display clinically complex and challenging to treat movement disorders in over 80% of the cases (Zhang et al. in Neurocrit Care 29(2):264-272, 2018). Treatment options include immunotherapy and symptomatic agents affecting dopamine or acetylcholine neurotransmission. There has been no prior published guidance for management of these movement disorders for the intensivist. Herein, we discuss the immune-mediated encephalitis most likely to cause critical illness, clinical features and mechanisms of movement disorders and propose a management algorithm.
Assuntos
Corticosteroides/uso terapêutico , Doenças Autoimunes do Sistema Nervoso/tratamento farmacológico , Antagonistas Colinérgicos/uso terapêutico , Dopaminérgicos/uso terapêutico , Encefalite/tratamento farmacológico , Imunossupressores/uso terapêutico , Transtornos dos Movimentos/tratamento farmacológico , Bloqueadores Neuromusculares/uso terapêutico , Antagonistas Adrenérgicos alfa/uso terapêutico , Antagonistas Adrenérgicos beta/uso terapêutico , Analgésicos Opioides/uso terapêutico , Anticonvulsivantes/uso terapêutico , Antiparkinsonianos/uso terapêutico , Autoanticorpos/imunologia , Doenças Autoimunes do Sistema Nervoso/complicações , Doenças Autoimunes do Sistema Nervoso/imunologia , Doenças Autoimunes do Sistema Nervoso/fisiopatologia , Benzodiazepinas/uso terapêutico , Catatonia/tratamento farmacológico , Catatonia/etiologia , Catatonia/fisiopatologia , Coreia/tratamento farmacológico , Coreia/etiologia , Coreia/fisiopatologia , Estado Terminal , Antagonistas de Dopamina/uso terapêutico , Discinesias/tratamento farmacológico , Discinesias/etiologia , Discinesias/fisiopatologia , Distonia/tratamento farmacológico , Distonia/etiologia , Distonia/fisiopatologia , Emergências , Encefalite/complicações , Encefalite/imunologia , Encefalite/fisiopatologia , Humanos , Hipnóticos e Sedativos/uso terapêutico , Imunoglobulinas Intravenosas/uso terapêutico , Fatores Imunológicos/uso terapêutico , Unidades de Terapia Intensiva , Transtornos dos Movimentos/etiologia , Transtornos dos Movimentos/fisiopatologia , Mioclonia/tratamento farmacológico , Mioclonia/etiologia , Mioclonia/fisiopatologia , Síndromes Paraneoplásicas do Sistema Nervoso/complicações , Síndromes Paraneoplásicas do Sistema Nervoso/tratamento farmacológico , Síndromes Paraneoplásicas do Sistema Nervoso/imunologia , Síndromes Paraneoplásicas do Sistema Nervoso/fisiopatologia , PlasmafereseRESUMO
ABSTRACT Objective: To determine the events associated with the occurrence of intracranial hypertension (ICH) in pediatric patients with severe cranioencephalic trauma. Methods: This was a prospective cohort study of patients 18 years old and younger with cranioencephalic trauma, scores below nine on the Glasgow Coma Scale, and intracranial pressure monitoring. They were admitted between September, 2005 and March, 2014 into a Pediatric Intensive Care Unit. ICH was defined as an episode of intracranial pressure above 20 mmHg for more than five minutes that needed treatment. Results: A total of 198 children and adolescents were included in the study, of which 70.2% were males and there was a median age of nine years old. ICH occurred in 135 (68.2%) patients and maximum intracranial pressure was 36.3 mmHg, with a median of 34 mmHg. A total of 133 (97.8%) patients with ICH received sedation and analgesia for treatment of the condition, 108 (79.4%) received neuromuscular blockers, 7 (5.2%) had cerebrospinal fluid drainage, 105 (77.2%) received mannitol, 96 (70.6%) received hyperventilation, 64 (47.1%) received 3% saline solution, 20 (14.7%) received barbiturates, and 43 (31.9%) underwent a decompressive craniectomy. The events associated with the occurrence of ICH were tomographic findings at the time of admission of diffuse or hemispheric swelling (edema plus engorgement). The odds ratio for ICH in patients with Marshall III (diffuse swelling) tomography was 14 (95%CI 2.8-113; p<0.003), and for those with Marshall IV (hemispherical swelling) was 24.9 (95%CI 2.4-676, p<0.018). Mortality was 22.2%. Conclusions: Pediatric patients with severe cranioencephalic trauma and tomographic alterations of Marshall III and IV presented a high chance of developing ICH.
RESUMO Objetivo: Determinar eventos associados à ocorrência de hipertensão intracraniana (HIC) em pacientes pediátricos com traumatismo cranioencefálico grave. Métodos: Trata-se de coorte prospectiva de pacientes de até 18 anos, com traumatismo cranioencefálico, pontuação abaixo de nove na Escala de Coma de Glasgow e monitoração da pressão intracraniana, admitidos entre setembro de 2005 e março de 2014 em unidade de terapia intensiva pediátrica. A HIC foi definida como episódio de pressão intracraniana acima de 20 mmHg por mais de cinco minutos e com necessidade de tratamento. Resultados: Incluídas 198 crianças e adolescentes, 70,2% masculinos, mediana de idade de nove anos. A HIC ocorreu em 135 (68,2%) pacientes; valor máximo de pressão intracraniana de 36,3; mediana 34 mmHg. Receberam sedação e analgesia para tratamento da HIC 133 (97,8%) pacientes, 108 (79,4%) receberam bloqueadores neuromusculares, 7 (5,2%) drenagem de líquor, 105 (77,2%) manitol, 96 (70,6%) hiperventilação, 64 (47,1%) solução salina a 3%, 20 (14,7%) barbitúricos e 43 (31,9%) foram submetidos à craniectomia descompressiva. Os eventos associados à ocorrência de HIC foram os achados tomográficos à admissão de swelling (edema mais ingurgitamento) difuso ou hemisférico. A razão de chance para que pacientes com classificação tomográfica Marshall III (swelling difuso) apresentassem HIC foi 14 (IC95% 2,8-113; p<0,003) e para aqueles com Marshall IV (hemisférico) foi 24,9 (IC95% 2,4-676; p<0,018). A mortalidade foi de 22,2%. Conclusões: Pacientes pediátricos com traumatismo cranioencefálico grave e alterações tomográficas tipo Marshall III e IV apresentaram grande chance de desenvolver HIC.
Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Criança , Adolescente , Pressão Intracraniana/fisiologia , Hipertensão Intracraniana/terapia , Hipertensão Intracraniana/epidemiologia , Traumatismos Craniocerebrais/complicações , Índice de Gravidade de Doença , Unidades de Terapia Intensiva Pediátrica/estatística & dados numéricos , Tomografia Computadorizada por Raios X/métodos , Escala de Coma de Glasgow , Prevalência , Estudos Prospectivos , Hipertensão Intracraniana/diagnóstico por imagem , Craniectomia Descompressiva/métodos , Vazamento de Líquido Cefalorraquidiano , Traumatismos Craniocerebrais/mortalidade , Traumatismos Craniocerebrais/epidemiologia , Bloqueadores Neuromusculares/uso terapêuticoRESUMO
PURPOSE OF REVIEW: The purpose of this review is to discuss the optimal use of neuromuscular blocking agents (NMBA) during ambulatory surgery, and to provide an update on the routine use of neuromuscular monitoring and the prevention of residual paralysis. RECENT FINDINGS: The number of major surgical procedures performed in ambulatory patients is likely to increase in the coming years, following the development of laparoscopic and thoracoscopic procedures. To successfully complete these procedures, the proper use of NMBA is mandatory. The use of NMBA not only improves intubating conditions but also ventilation. Recent studies demonstrate that NMBA are much more the solution rather than the cause of airway problems. There is growing evidence that the paralysis of the diaphragm and the abdominal wall muscles, which are resistant to NMBA is of importance during laparoscopic surgery. Further studies are still required to determine when deep neuromuscular block [posttetanic count (PTC) < 5] is required perioperatively. There is now a consensus to use perioperatively neuromuscular monitoring and particularly objective neuromuscular monitoring in combination with reversal agents to avoid residual paralysis and its related morbidity (e.g. respiratory complications in the PACU). SUMMARY: Recent data suggest that it is now possible to obtain a tight control of neuromuscular block to maintain optimal relaxation tailored to the surgical requirements and to obtain a rapid and reliable recovery at the end of the procedure.
Assuntos
Procedimentos Cirúrgicos Ambulatórios , Bloqueio Neuromuscular , Bloqueadores Neuromusculares/uso terapêutico , Humanos , Monitoração NeuromuscularRESUMO
Paraesophageal hernia repairs are complex surgical cases frequently performed on patients of advanced age with multiple comorbidities, both of which create difficulties in the anesthetic management. Preoperative evaluation is challenging because of overlapping cardiopulmonary symptoms. The patient's symptoms and anatomy lead to an increased aspiration risk and the potential need for a rapid sequence induction. Depending on the surgical approach, lung isolation may be required. Communication with the surgeon is vital throughout the case, especially when placing gastric tube and bougies. Multimodal analgesia should include regional and/or neuraxial techniques, in addition to the standard intravenous and oral pain medications.
Assuntos
Anestesia Geral/métodos , Hérnia Hiatal/cirurgia , Herniorrafia/métodos , Manuseio das Vias Aéreas/métodos , Hidratação/métodos , Humanos , Intubação Gastrointestinal/métodos , Laparoscopia , Bloqueadores Neuromusculares/uso terapêutico , Dor Pós-Operatória/terapia , Respiração Artificial/métodos , Medição de RiscoRESUMO
Advances in imaging and technique have pushed the boundaries of the types of surgical interventions available to fetuses with congenital and developmental abnormalities. This review focuses on fundamental aspects of fetal anesthesia, including the physiologic changes of pregnancy, uteroplacental perfusion, and fetal physiology. We discuss the types of fetal surgeries and procedures currently being performed and discuss the specific anesthetic approaches to different categories of fetal surgeries. We also discuss ethical aspects of fetal surgery and anesthesia.
Assuntos
Anestesia por Condução/métodos , Anestesia Geral/métodos , Anestésicos/uso terapêutico , Doenças Fetais/cirurgia , Terapias Fetais/métodos , Feto/cirurgia , Analgésicos Opioides/uso terapêutico , Cesárea/métodos , Feminino , Terapias Fetais/ética , Viabilidade Fetal , Fetoscopia/métodos , Idade Gestacional , Humanos , Injeções Intramusculares , Procedimentos Cirúrgicos Minimamente Invasivos/métodos , Agulhas , Bloqueadores Neuromusculares/uso terapêutico , Circulação Placentária/fisiologia , Gravidez/fisiologia , Cirurgia Assistida por ComputadorRESUMO
INTRODUCTION: The monitoring of the curarisation is a unique opportunity to investigate the function of the neuromuscular junction (NMJ) during cancer surgery, especially in frailty-induced and age-related sarcopenia. METHOD: We conducted a comprehensive literature review in PubMed, without any limit of time related to frailty, sarcopenia, age and response to neuromuscular blockers in the context of cancer surgery. RESULTS: Several modifications appear with age: changes in cardiac output, a decrease in muscle mass and increase in body fat, the deterioration in renal and hepatic function, the plasma clearance and the volume of distribution in elderly are smaller. These changes can be exacerbated in cancer patients. We also find modifications of the NMJ: dysfunctional mitochondria, modifications in the innervation of muscle fibers and motor units, uncoupling of the excitation-contraction of muscle fibers, inflammation. Neuromuscular blocking agents (NMBAs) compete with acetylcholine and prevent it from fixing itself on its receptor. Many publications reported guidelines for using NMBAs in the elderly, based on studies comparing old people with young people. No one screened frailty before, and thus, no studies compared frail elderly and non-frail elderly undergoing cancer surgery. CONCLUSION: Despite many studies about curarisation in the specific populations, and many arguments for a potential interest for investigation, no studies investigated specifically the response to NMBAs in regard of the frailty-induced and age-related sarcopenia.
Assuntos
Idoso Fragilizado , Neoplasias/cirurgia , Bloqueadores Neuromusculares/uso terapêutico , Sarcopenia/tratamento farmacológico , Fatores Etários , Idoso , Humanos , Inflamação , Junção Neuromuscular/fisiopatologiaRESUMO
Airway management is the cornerstone to resuscitation efforts for many critically ill pediatric patients presenting for emergency care. Pediatric endotracheal intubation is uncommon in emergency medicine, making it challenging to maintain comfort with this critical procedure. This article offers strategies to facilitate pediatric airway management by addressing predictable anatomic and physiologic differences in children. Also reviewed are alternative approaches to airway management (eg, noninvasive ventilation and videolaryngoscopy) that might be used in cases of recognized difficult airways. Finally, recommendations for maintaining procedural skills in providers who may have limited clinical exposure to critically ill children requiring airway interventions are provided.
Assuntos
Manuseio das Vias Aéreas/métodos , Antiarrítmicos/uso terapêutico , Atropina/uso terapêutico , Criança , Medicina de Emergência , Capacidade Residual Funcional , Humanos , Hipnóticos e Sedativos/uso terapêutico , Máscaras Laríngeas , Laringoscopia , Laringe/anatomia & histologia , Pulmão/anatomia & histologia , Bloqueadores Neuromusculares/uso terapêutico , Ventilação não Invasiva , Pediatria , Gravação em VídeoRESUMO
Introducción: La administración de agentes anestésicos de forma endovenosa dio inicio a una nueva modalidad que implicó la administración de anestésicos en forma de infusiones continuas. Objetivo: Actualizar la información sobre la función de los bloqueadores neuromusculares cuando se administran en infusión continua en anestesia general endovenosa total. Desarrollo: Los bloqueadores neuromusculares se pueden administrar en infusión continua para mantener una concentración plasmática estable y lograr una adecuada relajación del paciente durante el procedimiento quirúrgico, así como una recuperación más rápida y segura de forma espontánea, basándose en el inicio de acción del fármaco utilizado, pero fundamentalmente del alcance de su efecto máximo. A pesar de ello es importante administrar una dosis de carga inicial que deben oscilar entre 2 y 3 DE 95 (dosis efectiva para disminuir la respuesta al estímulo en 95 por ciento de su valor inicial) y continuar con la administración en infusión continúa como parte del mantenimiento de la anestesia. Conclusiones: Independientemente de los diferentes criterios entre autores, la mayoría coinciden que las infusiones continuas logran mantener mayor estabilidad en sangre y por ende, menor dosis de bloqueadores neuromuscular, menores tiempos reales de reversión y menos efectos adversos(AU)
Introduction: The administration of anesthetic agents intravenously started a new modality that involved the administration of anesthetics in the form of continuous infusions. Objective: To update the information on the function of neuromuscular blocking drugs when administered in continuous infusion in total intravenous general anesthesia. Development: Neuromuscular blocking drugs can be administered in continuous infusion to maintain a stable plasma concentration and achieve adequate relaxation of the patient during the surgical procedure, as well as a faster and safer spontaneous recovery, based on the action onset of the drug used, but fundamentally on its maximum effect. Despite this, it is important to administer an initial loading dose that must range from 2 to 3 DE 95 (effective dose to decrease the response to the stimulus in 95 percent of its initial value) and continue with the administration in continuous infusion as part of the maintenance of anesthesia. Conclusions: Regardless the different criteria among authors, most agree that continuous infusions are effective in maintaining greater blood stability and, therefore, lower doses of neuromuscular blocking drugs, shorter real reversal times and fewer adverse effects(AU)
Assuntos
Humanos , Infusões Intravenosas/métodos , Anestésicos/administração & dosagem , Bloqueadores Neuromusculares/uso terapêuticoRESUMO
BACKGROUND: To explore the effect of neuromuscular blocking agents (NMBAs) on adult patients with acute respiratory distress syndrome (ARDS) by meta-analysis. METHODS: Three databases including Cochrane central register of controlled trials, PubMed, and Wanfang Data were searched to find relevant articles. We included randomized controlled trials that evaluated NMBAs compared with placebo or usual treatment in adult patients with ARDS. RESULTS: Five trials totaling 551 patients were identified eligible for inclusion. All the five trials were protective ventilation strategies based. All patients (the ratio of partial pressure of arterial oxygen/fraction of inspired oxygen ≤ 200 mm Hg) met American-European Consensus Conference or the Berlin definition oxygenation criteria for ARDS. Neuromuscular blocking agents significantly reduced intensive care unit mortality (relative risk, 0.73; 95% confidence intervals [CI], 0.58-0.93; p = 0.009; I = 0.0%; 4 trials, 455 patients) and 21- to 28-day mortality (relative risk, 0.63; 95% CI, 0.49-0.82; p = 0.001; I = 0.0%; 4 trials, 527 patients). At 48 hours, NMBAs improved oxygenation (weighted mean differences [WMD], 27.98; 95% CI, 7.45-48.51; p = 0.008; I = 44.2%; 4 trials, 212 patients). However, NMBAs have no effect on reduction of oxygenation at 24 hours (WMD, 26.83; 95% CI, -5.89 to 59.55; p = 0.108; I = 82.4%; 4 trials, 447 patients), and plateau pressure (WMD, 0.43; 95% CI, -0.46 to 1.31; p = 0.345; 4 trials, 455 patients) as well as positive end expiratory pressure (WMD, 0.10; 95% CI, -0.47 to 0.67; p = 0.73; 4 trials, 455 patients) at 48 hours. CONCLUSION: Protective ventilation strategies based NMBAs treatment reduces mortality in patients with moderate to severe ARDS. LEVEL OF EVIDENCE: Systematic reviews & meta-analysis, level III.